Technical Analysis for LRMR - Larimar Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 7.92 | -2.58% | -0.21 |
LRMR closed down 2.58 percent on Wednesday, May 8, 2024, on 49 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Stochastic Sell Signal | Bearish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -2.58% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.58% |
| Alert | Time |
|---|---|
| Down 3% | about 18 hours ago |
| Outside Day | about 19 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| Possible NR7 | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Drug Discovery Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Drug Discovery Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.68 |
| 52 Week Low | 2.18 |
| Average Volume | 433,787 |
| 200-Day Moving Average | 5.39 |
| 50-Day Moving Average | 8.10 |
| 20-Day Moving Average | 7.06 |
| 10-Day Moving Average | 7.33 |
| Average True Range | 0.51 |
| RSI (14) | 57.81 |
| ADX | 21.91 |
| +DI | 28.67 |
| -DI | 16.28 |
| Chandelier Exit (Long, 3 ATRs) | 6.79 |
| Chandelier Exit (Short, 3 ATRs) | 7.45 |
| Upper Bollinger Bands | 8.28 |
| Lower Bollinger Band | 5.85 |
| Percent B (%b) | 0.85 |
| BandWidth | 34.29 |
| MACD Line | 0.05 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 0.2409 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.59 | ||||
| Resistance 3 (R3) | 8.64 | 8.47 | 8.48 | ||
| Resistance 2 (R2) | 8.47 | 8.30 | 8.44 | 8.44 | |
| Resistance 1 (R1) | 8.19 | 8.19 | 8.11 | 8.14 | 8.40 |
| Pivot Point | 8.02 | 8.02 | 7.98 | 8.00 | 8.02 |
| Support 1 (S1) | 7.75 | 7.85 | 7.66 | 7.70 | 7.44 |
| Support 2 (S2) | 7.58 | 7.75 | 7.55 | 7.40 | |
| Support 3 (S3) | 7.30 | 7.58 | 7.36 | ||
| Support 4 (S4) | 7.25 |
